Filing Flows › Rhythm Pharmaceuticals (RYTM) › Guidance & outlook
Rhythm Pharmaceuticals (RYTM) guidance and outlook
Rhythm Pharmaceuticals' 10-Q filed Nov 3, 2026 makes 25 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 3, 2026
- Further, we estimate that 80% to 90% of PWS patients are living with hyperphagia and obesity, or approximately 8,500 – 12,750 patients.
- Based on the central role of MC4R pathway dysfunction in PWS, we believe that targeting this biology represents a compelling therapeutic approach.
- In addition, we plan to continue to evaluate the potential for MC4R agonism in the genes and gene families previously identified through the exploratory Phase 2 DAYBREAK trial, including the SEMA3 family, PHIP, TBX3 or PLXNA family.
- The LGC Amendment and term-loan facility mentioned above are intended to support the continued advancement of our MC4R portfolio, including the planned Phase 3 development of bivamelagon.
- We currently anticipate the following, near-term milestones:
- We expect we may need to continue to fund our operations through the sale of equity, debt financings or other sources.
- We expect to continue to incur significant expenses and operating losses for the foreseeable future.
- Following these initial approvals, sales of IMCIVREE have grown, and we expect will continue to grow.
- We expect cost of sales to increase in 2026 as we continue to sell inventory that is produced after we began capitalizing manufacturing costs for IMCIVREE commercial inventory.
- We expect research and development costs to increase significantly for the foreseeable future as our setmelanotide and other development programs progress.
- However, we do not believe that it is possible at this time to accurately project total program-specific expenses to commercialization and there can be no guarantee that we can meet the funding needs associated with these expenses.
- As we further implement and execute our commercialization plans to market setmelanotide in new territories and as we explore new collaborations to develop and commercialize setmelanotide, we anticipate that these expenses will materially increase.
Rhythm Pharmaceuticals' latest quarter
Rhythm Pharmaceuticals, Q3 2026: revenue $92.1M (+80% year over year), operating margin -42.6%, net loss $41.4M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Questions
What does Rhythm Pharmaceuticals expect?
Further, we estimate that 80% to 90% of PWS patients are living with hyperphagia and obesity, or approximately 8,500 – 12,750 patients. Based on the central role of MC4R pathway dysfunction in PWS, we believe that targeting this biology represents a compelling therapeutic approach. In addition, we plan to continue to evaluate the potential for MC4R agonism in the genes and gene families previously identified through the exploratory Phase 2 DAYBREAK trial, including the SEMA3 family, PHIP, TBX3 or PLXNA family.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.